Note that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...

Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.

The move reveals both the power of philanthropic groups to sway legislators and a split in the administration’s coalition.

A proactive strategy that promotes U.S. pharmaceutical manufacturing is a crucial pillar within a resilient and diversified ...

Skadden partner Joseph Barloon, former Jones Day partner Brett Shumate and former Wilmer partner Jeffrey Kessler, among ...

The best-financed lobbyists in the United States are protecting the pharmaceutical sector, but that may change ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.